 |
MR Vol.13 No.4 indexに戻る
 |
MODERN RHEUMATOLOGY
Vol.13 No.4 |
 |
|
|
 |
|
|
Efficacy of mizoribine treatment in patients
with SjOgrens syndrome: an open pilot trial |
|
|
| Shingo Nakayamada1, Kazuyoshi Saito1, Keisuke
Nakatsuka1, Kazuhisa Nakano1, Mikiko Tokunaga1, Norifumi Sawamukai1,
Shizuyo Tsujimura1, Masao Nawata1 and Yoshiya Tanaka1 |
| (1) First Department of Internal Medicine, University
of Occupational and Environmental Health, School of Medicine, 1-1
Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan |
| |
| Received: 28 November 2002 Accepted: 31 March
2003 |
| |
| Abstract |
| The aim of this study was to evaluate the efficacy
and safety of mizoribine in patients with SjOgrens syndrome. Forty
patients with sicca syndrome, whose conditions were definitely diagnosed
as SjOgrens syndrome, were given mizoribine orally at a dosage of
150mg/day for 12 months. The percentage change in salivary secretion
after 3, 6, and 12 months of the therapy increased to +112.2% (P
0.001), +119.9% (P 0.01), and +147.3% (P 0.001), respectively, compared
with the baseline. Serum IgG levels decreased significantly throughout
the study, and the level was 1969.4 ± 620.0mg/dl after treatment
for 12 months compared with the pretreatment value of 2094.3 ± 746.6mg/dl
(P 0.05). The patients assessment of clinical signs and symptoms
on a 10-cm visual analog scale improved significantly from 7.2 ±
2.3cm at the start of the treatment to 5.0 ± 1.9cm after 12 months
(P 0.001). There was a similar improvement in the physicians assessment
using the 10-cm visual analog scale: 7.1 ± 1.6cm at the start of
the treatment and 5.2 ± 1.9cm after 12 months (P 0.001). With regard
to safety, no serious adverse reactions were observed. Although a
controlled study would be required to clarify the efficacy of mizoribine,
these preliminary observations indicate its efficacy for ameliorating
glandular symptoms through improvements in immune abnormalities in
patients with SjOgrens syndrome. |
| |
| Key words |
Mizoribine - SjOgrens syndrome - Xerostomia
|
|
|
 |
|
|
